Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Sarepta Therapeutics, Inc's Stock is Jumping Again

By Brian Feroldi – Sep 20, 2016 at 12:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares soar in response to a handful of analysts turning bullish.

Image source: Getty Images

What happened

Investors in Sarepta Therapeutics (SRPT -0.28%) are having another great day. Shares of the rare-disease focused biotech are up more than 12% as of 11:50 a.m. EDT Tuesday in the wake of catching a handful of analyst upgrades.

So what

Wall Street was caught off guard on Monday after news broke that the FDA had granted accelerated approval of Sarepta's Duchenne muscular dystrophy (DMD) drug Exondys 51. In response, analysts having been tripping over themselves in the last 24 hours to upgrade the company's shares. 

On Monday, at least three separate analysts raised their rating. The most dramatic change came from RBC Capital Markets. The investment firm upgraded its outlook to "outperform" and changed its price target to $83. That's far higher than its prior target of $5.

The good news kept rolling in on Tuesday, too. Needham reiterated its "buy" rating and raised its price target to $81. That's also substantially higher than its prior outlook of just $47.

When you combine the love pouring in from Wall Street with the company's extremely high short-ratio -- roughly 35% of Sarepta's shares have been sold short -- it's no surprise to see the company's stock moving higher.

Now what

Sarepta held a special conference call with investors on Monday evening to share more details about its commercialization plans. The company plans on selling Exondy's 51 in two different formats -- 2 mL and 10 mL -- and have announced a list price of $1,600 and $8,000, respectively, for each. That puts the annual cost of treatment at about $300,000 per patient, which is consistent with the pricing that PTC Therapeutics receives for the sale of its DMD drug Translarna in the E.U.

Management also stated on the call that they will be "exploring the sale" of the rare pediatric disease priority review voucher that they were awarded as part of the approval. Last year pharma giant AbbVie ponied up $350 million to get its hands on one of those vouchers, so this could be a significant source of non-dilutive funding for Sarepta.

Sarepta also stated that its team of national account managers will be opening up dialogues with payers to get the reimbursement process rolling. The company expects it to take 30 to 90 days for interested patients to receive coverage, which will create a small lag in the company's ability to recognize revenue.

All in all, there's a lot going on at Sarepta right now and new information is coming out every day. That hints that this company's stock is likely to remain volatile for the foreseeable future, so bulls and bears should plan accordingly.

Brian Feroldi has no position in any stocks mentioned. Like this article? Follow him on Twitter where he goes by the handle @Longtermmindset or connect with him on LinkedIn to see more articles like this.

The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Stocks Mentioned

Sarepta Therapeutics Stock Quote
Sarepta Therapeutics
$119.76 (-0.28%) $0.34
AbbVie Stock Quote
$165.40 (1.03%) $1.68
PTC Therapeutics Stock Quote
PTC Therapeutics
$39.41 (-0.68%) $0.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.